Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Laminotomy, laminectomy, interspinous devices; the MIS call point. Main billing specialties: neurosurgery and orthopedic spine.
Medicare fee-for-service decompression & minimally invasive spine cases in the 51 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (250 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 219 | 9,586−3.4%/yr | −3.4%/yr | 2.80.9× | 7% | 10,100 in 2030+0.8%/yr |
| Texas | 195 | 8,404−6.2%/yr | −6.2%/yr | 3.81.2× | 4% | 9,180 in 2030+1.5%/yr |
| Florida | 167 | 7,562−4%/yr | −4%/yr | 3.31.0× | 15% | 8,490 in 2030+1.9%/yr |
| New York | 113 | 4,671−4.3%/yr | −4.3%/yr | 2.50.8× | 3% | 4,720 in 2030+0.2%/yr |
| Pennsylvania | 95 | 4,474−6.6%/yr | −6.6%/yr | 3.21.0× | 2% | 4,650 in 2030+0.6%/yr |
| Ohio | 114 | 4,105−5.1%/yr | −5.1%/yr | 3.61.2× | 8% | 4,010 in 2030−0.4%/yr |
| Illinois | 81 | 3,603−6.4%/yr | −6.4%/yr | 2.50.8× | 7% | 3,990 in 2030+1.7%/yr |
| North Carolina | 90 | 3,162−8.5%/yr | −8.5%/yr | 3.11.0× | 17% | 3,120 in 2030−0.2%/yr |
| Virginia | 64 | 2,968−6.1%/yr | −6.1%/yr | 2.80.9× | 2% | 3,270 in 2030+1.7%/yr |
| Tennessee | 70 | 2,945−5.3%/yr | −5.3%/yr | 4.01.3× | 12% | 3,010 in 2030+0.4%/yr |
| Maryland | 71 | 2,940−4.2%/yr | −4.2%/yr | 3.31.1× | 5% | 3,010 in 2030+0.4%/yr |
| Georgia | 72 | 2,880−6.9%/yr | −6.9%/yr | 3.21.0× | 7% | 3,140 in 2030+1.5%/yr |
| Massachusetts | 67 | 2,826−4.4%/yr | −4.4%/yr | 2.90.9× | 0% | 3,400 in 2030+3.1%/yr |
| Arizona | 72 | 2,815−4.4%/yr | −4.4%/yr | 3.71.2× | 14% | 3,290 in 2030+2.6%/yr |
| Washington | 74 | 2,603−5.2%/yr | −5.2%/yr | 3.31.1× | 17% | 2,650 in 2030+0.3%/yr |
| New Jersey | 62 | 2,530−1.6%/yr | −1.6%/yr | 2.30.8× | 4% | 2,680 in 2030+1%/yr |
| Michigan | 55 | 2,499−11%/yr | −11%/yr | 2.80.9× | 7% | 2,340 in 2030−1.1%/yr |
| Indiana | 65 | 2,388−6%/yr | −6%/yr | 3.31.1× | 5% | 2,460 in 2030+0.5%/yr |
| Missouri | 56 | 2,193−7.1%/yr | −7.1%/yr | 3.41.1× | 5% | 2,190 in 20300%/yr |
| South Carolina | 56 | 2,163−7.6%/yr | −7.6%/yr | 3.11.0× | 7% | 2,560 in 2030+2.8%/yr |
| Colorado | 51 | 2,105−5.5%/yr | −5.5%/yr | 4.21.3× | 5% | 2,480 in 2030+2.7%/yr |
| Kansas | 33 | 1,688−5.7%/yr | −5.7%/yr | 4.11.3× | 1% | 1,840 in 2030+1.4%/yr |
| Oregon | 37 | 1,683−5.9%/yr | −5.9%/yr | 3.91.2× | 38% | 1,690 in 20300%/yr |
| Oklahoma | 44 | 1,608−8.9%/yr | −8.9%/yr | 3.21.0× | 1% | 1,650 in 2030+0.4%/yr |
| Minnesota | 40 | 1,579−8.6%/yr | −8.6%/yr | 3.31.1× | 9% | 1,920 in 2030+3.3%/yr |
| Alabama | 39 | 1,508−11%/yr | −11%/yr | 3.31.1× | 4% | 1,590 in 2030+0.9%/yr |
| Louisiana | 29 | 1,488−6.6%/yr | −6.6%/yr | 3.51.1× | 5% | 1,490 in 2030+0.1%/yr |
| Kentucky | 33 | 1,469−9.4%/yr | −9.4%/yr | 3.11.0× | 1% | 1,500 in 2030+0.4%/yr |
| Wisconsin | 46 | 1,360−6.9%/yr | −6.9%/yr | 2.30.7× | 5% | 1,720 in 2030+4%/yr |
| Utah | 31 | 1,279−3.9%/yr | −3.9%/yr | 5.61.8× | 16% | 1,510 in 2030+2.8%/yr |
| Arkansas | 30 | 1,254−7.9%/yr | −7.9%/yr | 3.21.0× | 7% | 1,220 in 2030−0.4%/yr |
| Iowa | 23 | 1,138−4.2%/yr | −4.2%/yr | 2.50.8× | 7% | 1,050 in 2030−1.3%/yr |
| Nevada | 27 | 1,021−8%/yr | −8%/yr | 3.41.1× | 4% | 1,050 in 2030+0.5%/yr |
| Connecticut | 25 | 1,006−5.7%/yr | −5.7%/yr | 2.90.9× | 5% | 1,000 in 2030−0.1%/yr |
| Nebraska | 23 | 974−3.8%/yr | −3.8%/yr | 3.71.2× | 9% | 890 in 2030−1.4%/yr |
| Idaho | 23 | 876−1.5%/yr | −1.5%/yr | 4.21.3× | 1% | 1,130 in 2030+4.3%/yr |
| Mississippi | 19 | 811−12%/yr | −12%/yr | 2.10.7× | 24% | 720 in 2030−2%/yr |
| Delaware | 11 | 619+0.2%/yr | +0.2%/yr | 3.51.1× | 16% | 820 in 2030+4.7%/yr |
| Montana | 11 | 616−3.5%/yr | −3.5%/yr | 3.21.0× | 9% | 590 in 2030−0.8%/yr |
| New Hampshire | 13 | 531−10%/yr | −10%/yr | 2.30.7× | 19% | 900 in 2030+9.2%/yr |
| South Dakota | 18 | 528−7.2%/yr | −7.2%/yr | 4.01.3× | 0% | 760 in 2030+6.2%/yr |
| North Dakota | 9 | 384−6.4%/yr | −6.4%/yr | 3.81.2× | 13% | 320 in 2030−3.1%/yr |
| District of Columbia | 9 | 350−0.3%/yr | −0.3%/yr | 5.41.8× | 8% | 320 in 2030−1.3%/yr |
| Alaska | 10 | 340+0.8%/yr | +0.8%/yr | 2.80.9× | 13% | 430 in 2030+3.8%/yr |
| Wyoming | 9 | 331−4.1%/yr | −4.1%/yr | 3.01.0× | 10% | 310 in 2030−0.8%/yr |
| Rhode Island | 10 | 326−4.7%/yr | −4.7%/yr | 3.41.1× | 0% | 340 in 2030+0.7%/yr |
| West Virginia | 6 | 276−14%/yr | −14%/yr | 1.30.4× | 0% | 310 in 2030+2.1%/yr |
| Maine | 7 | 255−15%/yr | −15%/yr | 1.60.5× | 0% | 290 in 2030+2%/yr |
| New Mexico | 7 | 250−13%/yr | −13%/yr | 1.00.3× | 0% | 350 in 2030+5.7%/yr |
| Hawaii | 7 | 234−1.1%/yr | −1.1%/yr | 1.80.6× | 12% | 140 in 2030−8.4%/yr |
| Vermont | 6 | 114−10%/yr | −10%/yr | 1.00.3× | 0% | 50 in 2030−12%/yr |
Professional codes (what the surgeon bills): CPT 63030, 63047, 63020, 63045, 22867; the hospital bills MS-DRG 518, 519, 520.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 60 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 13 companies. The most active:
Product codes: NQO (prosthesis, spinous process spacer/plate), PEK (spinous process plate). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved +4 pts since 2019, to 8%.
The 10 busiest do 14% of the cases CMS names in California; 131 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Lumbar fusion | 2,352 | 95,082−1.5%/yr | −1.5%/yr | 107,700 in 2030+2.1%/yr |
| Cervical fusion & disc arthroplasty | 962 | 47,639−4%/yr | −4%/yr | 52,600 in 2030+1.7%/yr |
| Kyphoplasty & vertebroplasty | 453 | 42,837−5.7%/yr | −5.7%/yr | 44,800 in 2030+0.7%/yr |
| SI joint fusion | 147 | 7,710+13%/yr | +13%/yr | 14,700 in 2030+11%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 9 companies reported engagement with surgeons in the covered states worth $6.6M in consulting, speaking, meals and travel tied to these products, about $2,594 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 5 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.